924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
At the J.P. Morgan Healthcare Conference on January 13, 2026, Acadia Pharmaceuticals said it anticipates 2025 net sales will exceed $1 billion, consistent with its prior guidance. The company also posted a corporate slide presentation on its investor website.
Acadia anticipates 2025 net sales will exceed $1 billion.
The $1 billion figure is consistent with the company's prior guidance; the filing gives no new figures.
The information was presented at the J.P. Morgan Healthcare Conference on January 13, 2026, and a slide presentation was posted at ir.acadia.com.
Revvity said it expects full-year 2025 adjusted earnings per share to exceed the upper end of its $4.90-$5.00 guidance from October 27, 2025. It also preliminarily estimated fourth-quarter revenue of approximately $772 million and full-year 2025 revenue of approximately $2,855 million, with final results due February 2, 2026. For shareholders, this is an early signal that profit and revenue are running ahead of the prior outlook, though the figures remain preliminary until the full release.
Full-year 2025 adjusted EPS now expected to exceed the upper end of the $4.90-$5.00 guidance
Fourth-quarter 2025 revenue expected at approximately $772 million, up approximately 6% reported and 4% organic
Full-year 2025 revenue expected at approximately $2,855 million, up approximately 4% reported and 3% organic
Full fourth-quarter and full-year 2025 results and earnings call scheduled for February 2, 2026
Acadia Healthcare said it is reaffirming its 2025 financial guidance, first set in its November 5, 2025 earnings release and updated by a December 2, 2025 press release, in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The filing contains no new 2025 results and no change to the guidance ranges, so it gives shareholders a reconfirmation of the company's existing outlook.
Revenue guidance reaffirmed at $3.28 billion to $3.30 billion for 2025.
Adjusted EBITDA guidance reaffirmed at $601 million to $611 million for 2025.
Adjusted earnings per share guidance reaffirmed at $1.94 to $2.04 for 2025.
Live webcast of the presentation starts at 5:15 p.m. Pacific Time on January 13, 2026, with a replay available for thirty days.
Amneal Pharmaceuticals said in a January 13, 2026 investor presentation filing that it expects to meet or exceed the 2025 full-year financial guidance it gave on October 30, 2025. It also estimates net leverage of about 3.6x as of December 31, 2025, down from 3.9x a year earlier. The filing reaffirms the existing guidance ranges rather than raising them, and the figures remain estimates subject to year-end close.
Guidance ranges unchanged from October 30, 2025: net revenue $3.0 billion to $3.1 billion and adjusted diluted EPS $0.75 to $0.80
Adjusted EBITDA guidance of $675 million to $685 million; operating cash flow guidance of $300 million to $330 million
Estimated net leverage of approximately 3.6x as of December 31, 2025, compared with 3.9x as of December 31, 2024
Figures are based on current estimates and remain subject to change until year- and quarter-end closing processes are complete
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.